Evidence map›Paper›PMID 41646269›Full record

ArticleESMO gastrointestinal oncology2025

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study.

K Nakanishi, N Sugimoto, Y Kodera, H Kawakami, A Makiyama, H Konishi, S Morita, Y Narita, K Minashi, M Imano and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

K NakanishiDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
N SugimotoDepartment of Genetic Oncology, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.
Y KoderaDepartment of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
H KawakamiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama City, Osaka, Japan.
A MakiyamaCancer Center, Gifu University Hospital, Gifu, Japan.
H KonishiDepartment of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
S MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Yoshidakonoecho, Kyoto, Japan.
Y NaritaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
K MinashiClinical Trial Promotion Department and Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
M ImanoDepartment of Surgery, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
R InamotoDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
T NishinaDepartment of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Minamiumemotomachi, Matsuyama, Ehime, Japan.
T KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
M HagiwaraDepartment of Surgery, Nihonkai General Hospital, Sakata, Yamagata, Japan.
H KumeOncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Chuo City, Tokyo, Japan.
K YamaguchiOncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Chuo City, Tokyo, Japan.
W HashimotoData Intelligence Department, Daiichi Sankyo Co. Ltd., Chuo City, Tokyo, Japan.
K MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: EN-DEAVOR was a multi-institutional retrospective study evaluating the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in gastric cancer patients. This secondary analysis investigated prognostic factors for real-world progression-free survival (rwPFS) and objective response rate (ORR) for T-DXd as third- or later-line treatment. Patients and methods: Patients aged ≥20 years with histopathologically confirmed human epidermal growth factor receptor 2 (HER2)-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma, who had worsened after chemotherapy, were included. Patients received T-DXd as third- or later-line therapy between September 2020 and September 2021. Univariate and multivariate analyses identified prognostic factors for rwPFS and ORR. Results: Of the 307 patients, 75.6% were male and 69.1% were aged ≥65 years. The median duration of prior trastuzumab treatment was 6.5 months (range 0-81.5 months). Multivariate analysis showed HER2 immunohistochemistry (IHC) 3+ [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86], intestinal type lesions (HR 0.59, 95% CI 0.43-0.79), modified Glasgow Prognostic Score (mGPS) 0 and 1 (HR 0.71, 95% CI 0.53-0.95), and longer duration of prior trastuzumab treatment (≥ median) (HR 0.75, 95% CI 0.58-0.97) as positive prognostic factors for rwPFS. Longer prior trastuzumab treatment was also a positive prognostic factor for ORR (odds ratio 2.02, 95% CI 1.13-3.63). Conclusions: Patients with clinical benefits from prolonged trastuzumab treatment are likely to benefit from T-DXd. Similarly, HER2 IHC 3+, intestinal type lesions, and better mGPS (0 or 1) are associated with longer rwPFS. However, T-DXd should not be withheld even in patients without these factors, as a median PFS of 3.42 months was observed in those with the shortest prior trastuzumab exposure.

Indexed as

EN-DEAVORgastric or gastroesophageal junction cancerHER2 positivemodified Glasgow Prognostic Scoreprognostic factorstrastuzumab deruxtecan

Identifiers

PMID41646269
PMCPMC12836736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.